scholarly journals CT Findings From Interstitial Lung Diseases in Patients With Metastatic Breast Cancer Treated With Fam-Trastuzumab Deruxtecan: A Single Institutional Experience

2022 ◽  
Vol 25 ◽  
Author(s):  
Yoon Jung Jang ◽  
Jae Ho Jeong ◽  
Jeong Eun Kim ◽  
Jin-Hee Ahn ◽  
Kyung Hae Jung ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Lung Diseases ◽  
Metastatic Breast ◽  
Interstitial Lung Diseases ◽  
Ct Findings ◽  
Institutional Experience

Efficacy and safety of combined trastuzumab and paclitaxel therapy as a second-line treatment in women with metastatic Breast Cancer: A single institutional experience

Breast Cancer ◽  
2006 ◽  
Vol 13 (4) ◽  
pp. 329-333 ◽  
Author(s):  
Keiko Furukawa ◽  
Yoshinori Ito ◽  
Shunji Takahashi ◽  
Masataka Sawaki ◽  
Nobuyuki Mizunuma ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Line Treatment ◽  
Second Line ◽  
Efficacy And Safety ◽  
Institutional Experience

Use of alpelisib in the treatment of hormone receptor positive metastatic breast cancer: An institutional experience.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e15216-e15216
Author(s):  
Tsering G. Lama Tamang ◽  
Daniel Kyung ◽  
Lauren Eisenbud ◽  
Tianyi Tang ◽  
Ritesh Parajuli ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Pik3ca Mutation ◽  
Metastatic Breast ◽  
Pi3k Pathway ◽  
Real World Data ◽  
Tumor Registry ◽  
Hormone Receptor Positive ◽  
Heavily Pretreated ◽  
Institutional Experience

e15216 Background: Mutations in PI3K pathway is a known mechanism of resistance to endocrine therapy in breast cancer. Alpelisib is an alpha-specific PI3K inhibitor. Alpelisib with Fulvestrant is approved for treatment (Tx) of PIK3CA mutated HR+ metastatic breast cancer (MBC) that progress on hormonal therapy. Despite its approval by the FDA, real world data on the use of Alpelisib for the management of MBC is lacking. This abstract reviews the safety and efficacy of Alpelisib in the management of patients with MBC. Methods: A retrospective review of the tumor registry database at a single institution was conducted to identify patients with HR+ MBC. Detailed clinical and pathologic data of PIK3CA mutated patients treated with Alpelisib were obtained. Genomic profiling was done with Foundation One. Results: Table highlights the characteristics of the four patients. All were treated with Alpelisib and Fulvestrant after PIK3CA mutation was demonstrated. 3 patients were heavily pretreated with systemic Tx including CDK 4/6 inhibitors. All patients responded to Alpelisib and Fulvestrant despite treatment history. Mucositis, rash, hyperglycemia and pancytopenia were the observed adverse events (A/E). All A/E were adequately managed except in one patient that required discontinuation of Tx. None has clinically progressed. Conclusions: Our data suggests that Alpelisib and Fulvestrant is tolerated and improves outcomes in patients with HR+ MBC. Alpelisib and Fulvestrant could be an effective therapy in patients who have also progressed on systemic chemotherapy including CDK 4/6 inhibitors. Although our sample size is small, we hope that our experience could guide clinicians in the management of patients with HR+ MBC who harbor the PIK3CA mutation and are being treated with Alpelisib. [Table: see text]

EP1242 Palbociclib in the treatment of metastatic breast cancer. Institutional experience

2019 ◽  
Author(s):  
A Mainella ◽  
S Vigo ◽  
F Marmissolle ◽  
P Price ◽  
M Sansano ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Institutional Experience

Everolimus plus exemestane for hormone resistant metastatic breast cancer (MBC): A single institutional experience.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e11576-e11576
Author(s):  
Luisa Foltran ◽  
Manuela Bertola ◽  
Alessandro Del Conte ◽  
Giovanni Lo Re ◽  
Alessandro Bestetti ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Institutional Experience

Breast Reconstruction in Metastatic Breast Cancer: Report of an Institutional Experience and Review of Literature

2017 ◽  
Vol 15 (1) ◽  
Author(s):  
Begoña Díaz de la Noval ◽  
Laura Frías Aldeguer ◽  
Shirin Zarbakhsh Etemandi ◽  
César Casado Sánchez ◽  
José Ignacio Sánchez-Méndez ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Breast Reconstruction ◽  
Metastatic Breast ◽  
Review Of Literature ◽  
Institutional Experience
Sign in / Sign up

Export Citation Format

Share Document